Skip to main content
Figure 4 | BMC Infectious Diseases

Figure 4

From: Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years

Figure 4

Solicited adverse events (total vaccinated cohort). Footnote: (A). local adverse events, (B). general adverse events. CI, confidence interval; GI, gastrointestinal; QIV, Inactivated quadrivalent influenza vaccine; TIV-Vic, inactivated trivalent influenza vaccine Victoria lineage B strain; TIV-Yam, inactivated trivalent influenza vaccine Yamagata lineage B strain.

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us